Market Overview
Paranovus Entertainment Tech (ticker PAVS) slipped 3.73 % over the 24‑hour window ending at 02:04 AM Central European Time on Thursday, 22 April 2026. At the time of reporting, the stock traded at approximately USD 2.91 on major exchanges. The company’s total shares outstanding amount to 856.9 k, giving it a market capitalization of USD 2.4 million. In the most recent 24‑hour period, roughly USD 34.1 k of PAVS shares changed hands.
Historical Performance
- Year‑to‑date change: Since the end of last month, PAVS has declined 30.03 %, underscoring a prolonged bearish trend.
- Moving averages: The 200‑day simple moving average sits at USD 503.91, a level that sits well above the current price, indicating a prolonged downtrend.
- 52‑week range: The peak price reached USD 144,000 on 28 November 2025, while the trough was USD 2.76 on 19 October 2026. The current price is nearer to the lower end of this range, reflecting a significant discount to the all‑time high.
Comparative Analysis with Peer Companies
| Stock | % Move (24 hrs) | Current Price (USD) | Market Cap (USD) |
|---|---|---|---|
| Real Messenger (RMSG) | –1.61 % | 0.25 | 2.8 million |
| Calidi Biotherapeutics (CLDI) | –1.66 % | 0.77 | 2.9 million |
| Xcel Brands (XELB) | –1.06 % | 0.40 | 2.8 million |
| Interactive Strength (TRNR) | +1.14 % | 1.79 | 2.8 million |
| Iveda (IVDA) | +4.55 % | 0.24 | 2.7 million |
While PAVS shares a similar bearish trend to its peers, the magnitude of its decline is more pronounced. Notably, Interactive Strength and Iveda have bucked the downtrend with modest gains, suggesting that market sentiment may still favor certain niche players within the broader sector.
Company Profile
Paranovus Entertainment Technology Ltd. operates primarily in the Chinese pharmaceutical market, focusing on the research, development, manufacturing, and marketing of dietary supplements. In addition to its core pharmaceutical activities, the company has diversified into e‑commerce and automotive sales services. This multi‑faceted business model positions Paranovus at the intersection of health and technology, though its recent valuation indicates that investors are currently skeptical about the company’s ability to generate sustainable growth.
The recent price movement, coupled with a steep decline in market capitalization, signals a need for cautious evaluation by investors and analysts alike. As the company navigates its strategic trajectory, the next quarter’s earnings report will likely be pivotal in determining whether Paranovus can reverse its current downward spiral.
